GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Blog|Videos|July 14, 2023
T.S.A.
Author(s)Richard M. Berlin, MD
"At O'Hare, at Atlanta, at Dallas/Fort Worth, it happens every trip, at LaGuardia, Logan, and Washington Dulles, the customary strip..."
Advertisement
Any Good Poem
Richard Berlin, MD, shares Amit Majmudar's poem "
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 25 years in Psychiatric Times® in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is Freud on My Couch.
Advertisement
Related to this article
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5